JGC
BPMC

J. Goldman & Co’s Blueprint Medicines BPMC Stock Holding History

J. Goldman & Co’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,228
Closed -$496K – 456
2024
Q1 		$496K Buy
+5,228
New +$448K 0.02% 321
2017
Q2 		– Sell
-33,600
Closed -$1.34M – 307
2017
Q1 		$1.34M Buy
+33,600
New +$1.2M 0.07% 237

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

J. Goldman & Co's BPMC Position: Q2 2024 in Review

J. Goldman & Co sold out of Blueprint Medicines (BPMC) in Q2 2024, closing a stake of 5,228 shares — an estimated $496K sold.

J. Goldman & Co first reported a position in BPMC in Q1 2017 and held it in 2 quarters. The position peaked at $1.34M in Q1 2017. 305 funds tracked by Wall St. Rank hold BPMC as of Q2 2024.

  • J. Goldman & Co reported no remaining Blueprint Medicines position as of Q2 2024 after selling out during the quarter.
  • J. Goldman & Co sold 5,228 Blueprint Medicines shares in Q2 2024, an estimated $496K.
  • J. Goldman & Co first reported a position in Blueprint Medicines in Q1 2017 and held it in 2 quarters.
  • J. Goldman & Co's Blueprint Medicines position peaked at $1.34M in Q1 2017.
  • 305 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.